Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.
The clinical and neuro-cognitive correlates of the P50 and N100 auditory evoked responses gating deficits in schizophrenia have thus far eluded identification. Based on our prior results, we hypothesized that, in addition to the P50, gating of the N100 is significantly decreased in schizophrenia and that this deficit correlates with the negative symptoms dimension of schizophrenia. Amplitudes and gating measures of the P50 and N100 were compared between stable out-patients (N=45) (mainly on atypical antipsychotics) with chronic schizophrenia and age- and gender-matched healthy controls (N=49) and the clinical correlates examined. All subjects underwent the paired-stimulus paradigm in 3 or 4 different days. Data from day one and the mean of all days (MOAD) were examined. P50 and N100 amplitudes and gating measures were correlated with PANSS and Wisconsin Card Sorting Test data. Utilizing day one data, no amplitude or gating measures were significantly different between the groups. Utilizing MOAD data, both P50 and N100 gating were significantly decreased in schizophrenia patients. The N100 gating deficit correlated with the negative-symptoms cluster and measures of frontal lobe dysfunction. The data suggest a correlation between N100 gating deficit and the negative-cognitive deficits dimensions of schizophrenia. Data also suggest that improving the signal to noise ratio (MOAD data) increases the sensitivity for detecting gating abnormalities and assessing their clinical correlates.
Boutros
Nash N
NN
Wayne State University, Department of Psychiatry and Behavioral Neurosciences, Detroit, MI, USA. nboutros@med.wayne.edu
Brockhaus-Dumke
Anke
A
Gjini
Klevest
K
Vedeniapin
Andrei
A
Elfakhani
Mohamad
M
Burroughs
Scott
S
Keshavan
Matcheri
M
D000161:Acoustic Stimulation / Q000379:methods; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004569:Electroencephalography; D005072:Evoked Potentials, Auditory / Q000187:drug effects* / Q000502:physiology; D005260:Female; D020233:Gait Disorders, Neurologic / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D012189:Retrospective Studies; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy*; D055139:Sensory Gating / Q000187:drug effects / Q000502:physiology; D013223:Statistics as Topic; D055815:Young Adult
D014150:Antipsychotic Agents